Rimadyl Tablets 20 mg

Ülke: Birleşik Krallık

Dil: İngilizce

Kaynak: VMD (Veterinary Medicines Directorate)

Aktif bileşen:

Carprofen

Mevcut itibaren:

Pfizer Ltd

ATC kodu:

QM01AE91

INN (International Adı):

Carprofen

Yetkilendirme durumu:

Expired

Ürün özellikleri

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rimadyl Tablets 20mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 20mg Carprofen.
For the full list of all other excipients see section 6.1
3.
PHARMACEUTICAL FORM
Tablets.
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For analgesia and reduction of chronic inflammation, for example in
degenerative joint disease, in the dog.
Rimadyl tablets can also be used in the management of post-operative
pain.
4.3 CONTRAINDICATIONS
Do not exceed the stated dose.
The elimination time of NSAIDs, including carprofen, in the cat is
longer
than in the dog and the therapeutic index is narrower. In the absence
of
specific data the use of Rimadyl Tablets in the cat is
contra-indicated.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is a possibility of gastro-intestinal ulceration or
bleeding, or
where there is evidence of blood dyscrasia or hypersensitivity to the
product. As with other NSAIDs there is a risk of rare idiosyncratic
renal
or hepatic adverse events.
Do not administer other NSAIDs concurrently or within 24 hours of each
other. Some NSAIDs may be highly bound to plasma proteins and
compete with other highly bound drugs, which can lead to toxic
effects.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in dogs less than 6 weeks of age, or in aged dogs, may involve
additional risk. If such a use cannot be avoided, such dogs may
require
a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there
is a potential rise of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be
avoided.
NSAID’s can cause inhibition of phagocytosis and hence in the
treatment
of inflammatory conditions associated with bacterial infection,
appropriate concurrent antimicrobial therapy shoul